Open AccessPsychosocial Factors and the Care Cascade for Hepatitis C Treatment Colocated at a Syringe Service Program
Author(s) -
Daniel Winetsky,
Daniel Burack,
Pantelis Antoniou,
Bill Garcia,
Peter Gordon,
Matthew Scherer
Publication year - 2020
Publication title -
the journal of infectious diseases (online. university of chicago press)/the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1093/infdis/jiaa142
Subject(s) - medicine , psychosocial , hepatitis c , viremia , opioid use disorder , methadone , opiate substitution treatment , mental health , buprenorphine , psychiatry , opioid , immunology , human immunodeficiency virus (hiv) , receptor
Direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) is highly effective. However, people who inject drugs face significant barriers to DAA access.